Page last updated: 2024-11-06

hexamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hexamidine is a synthetic diamidine compound that has been investigated for its potential therapeutic applications. It is typically synthesized through a multi-step process involving the condensation of an aromatic amine with an appropriate dicarboxylic acid derivative. Hexamidine exhibits anti-protozoal activity, specifically against trypanosomes and leishmanias, and has been explored as a potential treatment for African trypanosomiasis (sleeping sickness) and leishmaniasis. Its mechanism of action involves inhibiting the growth of these parasites by interfering with their DNA and RNA synthesis. Studies have shown that hexamidine possesses a relatively low toxicity profile compared to other diamidine drugs. However, further research is needed to fully understand its pharmacokinetic properties and potential side effects. Ongoing research efforts focus on optimizing its efficacy and safety for therapeutic use.'

hexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65130
CHEMBL ID25105
CHEMBL ID494852
CHEBI ID87184
SCHEMBL ID144738
MeSH IDM0071011

Synonyms (43)

Synonym
hexamidine
hexamidine (inn/ban)
D07206
1,6-di(4-amidinophenoxy)hexane
3811-75-4
4-[6-(4-carbamimidoylphenoxy)hexoxy]benzamidine
DB03808
4,4'[1,6-hexanediylbis(oxy)]bisbenzenecarboximidamide
4,4'-(1,6-hexanediylbis(oxy))bis-benzenecarboximidamide
hexamidina [inn-spanish]
benzenecarboximidamide, 4,4'-(1,6-hexanediylbis(oxy))bis-
hexamidinum [inn-latin]
CHEMBL25105 ,
chebi:87184 ,
4-[6-(4-carbamimidoylphenoxy)hexoxy]benzenecarboximidamide
4-{6-[4-amino(imino)methylphenoxy]hexyloxy}phenyl-iminomethanamine
chembl494852
4,4''''[1,6-hexanediylbis(oxy)]bisbenzenecarboximidamide
4-[6-(4-carbamimidoyl-phenoxy)-hexyloxy]-benzamidine
bdbm50015234
4-{6-[4-ammino(imino)methylphenoxy]hexyloxy}phenyl-iminomethanammine
8-n-boc-5,6,7,8-tetrahydro-1,8-naphthyridin-2-propoinicacid
unii-3483c2h13h
hexamidine [inn:ban:dcf]
3483c2h13h ,
hexamidina
hexamidinum
hexamidine [inn]
hexamidine [inci]
hexamidine [who-dd]
hexamidine [mi]
1,6-di (4-amidinophenoxy)-n-hexane
OQLKNTOKMBVBKV-UHFFFAOYSA-N
SCHEMBL144738
4,4'-[hexane-1,6-diylbis(oxy)]di(benzene-1-carboximidamide)
4,4'-[hexane-1,6-diylbis(oxy)]dibenzenecarboximidamide
STL483397
DTXSID60191524
FT-0700701
FT-0700706
Q250360
4-{[6-(4-carbamimidoylphenoxy)hexyl]oxy}benzene-1-carboximidamide
EN300-19767204

Research Excerpts

Overview

Hexamidine Diisethionate functions as a biocide in cosmetics at concentrations of 0.03% to 0.1% in 38 cosmetic products.

ExcerptReferenceRelevance
"Hexamidine Diisethionate functions as a biocide in cosmetics at concentrations of 0.03% to 0.1% in 38 cosmetic products. "( Final report on the safety assessment of Hexamidine and Hexamidine Diisethionate.
, 2007
)
2.05

Effects

ExcerptReferenceRelevance
"Hexamidine (HEX) has been used as a preservative in topical preparations since the 1950s. "( Hexamidine salts - applications in skin health and personal care products.
Hadgraft, J; Lane, ME; Lever, R; Matts, PJ; Parisi, N, 2017
)
3.34

Bioavailability

ExcerptReferenceRelevance
" Hexamidine was poorly absorbed by human cadaver skin when in water-oil formulations or in a gel that simulated a cosmetic product formulation."( Final report on the safety assessment of Hexamidine and Hexamidine Diisethionate.
, 2007
)
1.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
polyetherAny ether that contains more than one ether linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein arginine N-methyltransferase 5Homo sapiens (human)IC50 (µMol)357.00000.00900.69158.6000AID1506648
ProthrombinHomo sapiens (human)Ki0.22400.00000.78469.0000AID211360
Urokinase-type plasminogen activatorHomo sapiens (human)Ki14.40000.01702.62687.0000AID228651
Protein arginine N-methyltransferase 1Homo sapiens (human)IC50 (µMol)52.00000.25003.61679.4000AID1506647; AID1882355
Suppressor of tumorigenicity 14 proteinHomo sapiens (human)Ki0.92400.00000.87113.3500AID108587
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (93)

Processvia Protein(s)Taxonomy
peptidyl-arginine N-methylationProtein arginine N-methyltransferase 5Homo sapiens (human)
spliceosomal snRNP assemblyProtein arginine N-methyltransferase 5Homo sapiens (human)
chromatin remodelingProtein arginine N-methyltransferase 5Homo sapiens (human)
DNA-templated transcription terminationProtein arginine N-methyltransferase 5Homo sapiens (human)
regulation of mitotic nuclear divisionProtein arginine N-methyltransferase 5Homo sapiens (human)
peptidyl-arginine methylationProtein arginine N-methyltransferase 5Homo sapiens (human)
circadian regulation of gene expressionProtein arginine N-methyltransferase 5Homo sapiens (human)
endothelial cell activationProtein arginine N-methyltransferase 5Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationProtein arginine N-methyltransferase 5Homo sapiens (human)
negative regulation of cell differentiationProtein arginine N-methyltransferase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein arginine N-methyltransferase 5Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosomeProtein arginine N-methyltransferase 5Homo sapiens (human)
positive regulation of oligodendrocyte differentiationProtein arginine N-methyltransferase 5Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeProtein arginine N-methyltransferase 5Homo sapiens (human)
Golgi ribbon formationProtein arginine N-methyltransferase 5Homo sapiens (human)
liver regenerationProtein arginine N-methyltransferase 5Homo sapiens (human)
regulation of signal transduction by p53 class mediatorProtein arginine N-methyltransferase 5Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathwayProtein arginine N-methyltransferase 5Homo sapiens (human)
regulation of DNA-templated transcriptionProtein arginine N-methyltransferase 5Homo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
in utero embryonic developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
DNA damage responseProtein arginine N-methyltransferase 1Homo sapiens (human)
cell surface receptor signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of cell population proliferationProtein arginine N-methyltransferase 1Homo sapiens (human)
RNA splicingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
viral protein processingProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of BMP signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
neuron projection developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of erythrocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of translationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of JNK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of hemoglobin biosynthetic processProtein arginine N-methyltransferase 1Homo sapiens (human)
cardiac muscle tissue developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein homooligomerizationProtein arginine N-methyltransferase 1Homo sapiens (human)
cellular response to methionineProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of TORC1 signalingProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationProtein arginine N-methyltransferase 1Homo sapiens (human)
chromatin remodelingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylation, to asymmetrical-dimethyl arginineProtein arginine N-methyltransferase 1Homo sapiens (human)
neural tube closureSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
proteolysisSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
protein catabolic processSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
keratinocyte differentiationSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
epithelial cell morphogenesis involved in placental branchingSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
p53 bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
transcription corepressor activityProtein arginine N-methyltransferase 5Homo sapiens (human)
protein bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
methyl-CpG bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
protein-arginine N-methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
protein-arginine omega-N symmetric methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
histone methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
identical protein bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
ribonucleoprotein complex bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
histone H4R3 methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
protein heterodimerization activityProtein arginine N-methyltransferase 5Homo sapiens (human)
E-box bindingProtein arginine N-methyltransferase 5Homo sapiens (human)
histone H3 methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
histone arginine N-methyltransferase activityProtein arginine N-methyltransferase 5Homo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
RNA bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
enzyme bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N monomethyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N asymmetric methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
histone methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
identical protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
histone H4R3 methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
mitogen-activated protein kinase p38 bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
GATOR1 complex bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
S-adenosyl-L-methionine bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
serine-type endopeptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
serine-type peptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nucleusProtein arginine N-methyltransferase 5Homo sapiens (human)
nucleoplasmProtein arginine N-methyltransferase 5Homo sapiens (human)
Golgi apparatusProtein arginine N-methyltransferase 5Homo sapiens (human)
cytosolProtein arginine N-methyltransferase 5Homo sapiens (human)
methylosomeProtein arginine N-methyltransferase 5Homo sapiens (human)
chromatinProtein arginine N-methyltransferase 5Homo sapiens (human)
cytoplasmProtein arginine N-methyltransferase 5Homo sapiens (human)
histone methyltransferase complexProtein arginine N-methyltransferase 5Homo sapiens (human)
cytosolProtein arginine N-methyltransferase 5Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 5Homo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
lysosomal membraneProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytosolProtein arginine N-methyltransferase 1Homo sapiens (human)
methylosomeProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
extracellular spaceSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
external side of plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
basolateral plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1506644Inhibition of PRMT1 (unknown origin) assessed as residual enzyme activity by measuring methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin at 100 uM pre-incubated for 3 mins before [3H]-SAM addition and measured after 15 mins by 2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID1506648Inhibition of PRMT5 (unknown origin) assessed as reduction in methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin pre-incubated for 3 mins before [3H]-SAM addition and measured after 45 mins by scintillation proximity assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID712268Growth inhibition of human MALME-3M cells overexpressing calcium-binding protein S100B after 4 days by SYBR green assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B.
AID1506645Inhibition of PRMT5 (unknown origin) assessed as reduction in methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin at 10 uM pre-incubated for 3 mins before [3H]-SAM addition and measured after 45 mins by scintillation proximity as2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID1506646Inhibition of PRMT5 (unknown origin) assessed as reduction in methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin at 100 uM pre-incubated for 3 mins before [3H]-SAM addition and measured after 45 mins by scintillation proximity a2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID108587compound was tested for inhibitory activity against Matriptase2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
AID54424Denaturation temperature change on binding on GC to poly(dGC)-poly(dGC)1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
AID101036Inhibition on leishmania mexicana amazonensis.1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID1506647Inhibition of PRMT1 (unknown origin) assessed as reduction in methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin at 10 uM pre-incubated for 3 mins before [3H]-SAM addition and measured after 15 mins by scintillation proximity as2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID211360compound was tested for inhibitory activity against Thrombin2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
AID1506643Inhibition of PRMT1 (unknown origin) assessed as residual enzyme activity by measuring methyl transfer from [3H]-SAM to biotinylated histone H4 peptide H4-20-Biotin at 10 uM pre-incubated for 3 mins before [3H]-SAM addition and measured after 15 mins by s2017MedChemComm, Feb-01, Volume: 8, Issue:2
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
AID54423Denaturation temperature change on binding to AT to poly (dA)-poly(dT)1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
AID712198Binding affinity to rat/bovine recombinant S100B expressed in Escherichia coli [HMS174(DE3)strain] by NMR spectroscopy2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B.
AID1882355Inhibition of PRMT1 (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
AID54427DNA binding activity as denaturation temperatures on AT to poly (dA)-poly(dT) normalized to ethidium bromide1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
AID54426Denaturation temperature change on binding to calf thymus DNA1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
AID228651compound was tested for inhibitory activity against Urokinase-type plasminogen activator (microPa)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
AID712267Growth inhibition of human MALME-3M cells transfected with S100B siRNA after 4 days by SYBR green assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B.
AID54425DNA binding property estimated by measuring denaturation temperature on GC to poly (dGC)-poly(dGC), normalized to ethidium bromide1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (18.84)18.7374
1990's16 (23.19)18.2507
2000's17 (24.64)29.6817
2010's18 (26.09)24.3611
2020's5 (7.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.54 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index97.04 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (59.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.00%)5.53%
Reviews3 (4.00%)6.00%
Case Studies16 (21.33%)4.05%
Observational0 (0.00%)0.25%
Other53 (70.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]